Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.

Ther Adv Med Oncol · 2026 · PMC12759121 · PMID 41487693

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

approaching significanceno p-value reported

As expected, treatment with 30 μM carboplatin for 72 h decreased the proportion of cells in the G1 phase approaching significance, and significantly increased the proportion of cells in the S phase compared to DMSO vehicle.

also in 1,619 other papers

showed a trendno p-value reported

Interestingly, ROR1 knockout KURAMOCHI cells still showed a trend towards reduced signalling upon ivacaftor treatment.

also in 33,481 other papers

did not reach statistical significanceno p-value reported

KURAMOCHI ROR1 KO cell lines showed a very similar trend for ivacaftor treatment compared to vehicle control, but the trends did not reach statistical significance.

also in 75,868 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.